Gerard Aurigemma to Hypertrophy, Left Ventricular
This is a "connection" page, showing publications Gerard Aurigemma has written about Hypertrophy, Left Ventricular.
Connection Strength
3.654
-
Aldrugh S, Valle JE, Parker MW, Harrington CM, Aurigemma GP. Prevalence of Left Ventricular Hypertrophy Caused by Systemic Hypertension Preceding the Development of Severe Aortic Stenosis. Am J Cardiol. 2021 07 01; 150:89-94.
Score: 0.680
-
Gaasch WH, Aurigemma GP. CMR imaging of extracellular volume and myocardial strain in hypertensive heart disease. JACC Cardiovasc Imaging. 2015 Feb; 8(2):181-3.
Score: 0.439
-
Chinali M, Aurigemma GP. Refining patterns of left ventricular hypertrophy using cardiac MRI: "brother, can you spare a paradigm?". Circ Cardiovasc Imaging. 2010 Mar; 3(2):129-31.
Score: 0.312
-
Aurigemma GP, Devereux RB, Wachtell K, Palmieri V, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahl?f B. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. Am J Hypertens. 2003 Mar; 16(3):180-6.
Score: 0.192
-
Aurigemma GP, Devereux RB, De Simone G, Roman MJ, O'Grady MJ, Koren M, Alderman M, Laragh J. Myocardial function and geometry in hypertensive subjects with low levels of afterload. Am Heart J. 2002 Mar; 143(3):546-51.
Score: 0.179
-
Aurigemma GP, Meyer TE, Sharma M, Sweeney A, Gaasch WH. Evaluation of extent of shortening versus velocity of shortening at the endocardium and midwall in hypertensive heart disease. Am J Cardiol. 1999 Mar 01; 83(5):792-4, A10.
Score: 0.145
-
Aurigemma GP, Gaasch WH, McLaughlin M, McGinn R, Sweeney A, Meyer TE. Reduced left ventricular systolic pump performance and depressed myocardial contractile function in patients > 65 years of age with normal ejection fraction and a high relative wall thickness. Am J Cardiol. 1995 Oct 01; 76(10):702-5.
Score: 0.115
-
Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol. 1995 Jul; 26(1):195-202.
Score: 0.113
-
Aurigemma GP, Gaasch WH, Villegas B, Meyer TE. Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. Curr Probl Cardiol. 1995 Jun; 20(6):361-440.
Score: 0.112
-
de Simone G, Izzo R, Aurigemma GP, De Marco M, Rozza F, Trimarco V, Stabile E, De Luca N, Trimarco B. Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities. J Hypertens. 2015 Apr; 33(4):745-54; discussion 754.
Score: 0.111
-
Aurigemma GP, Gaasch WH. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology. 1995; 86(4):310-7.
Score: 0.109
-
Bang CN, Gerdts E, Aurigemma GP, Boman K, de Simone G, Dahl?f B, K?ber L, Wachtell K, Devereux RB. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. Circ Cardiovasc Imaging. 2014 May; 7(3):422-9.
Score: 0.104
-
Perlini S, Chung ES, Aurigemma GP, Meyer TE. Alterations in early filling dynamics predict the progression of compensated pressure overload hypertrophy to heart failure better than abnormalities in midwall systolic shortening. Clin Exp Hypertens. 2013; 35(6):401-11.
Score: 0.094
-
Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, Dahl?f B, Aalto T, Ibsen H, Rokkedal JE, Devereux RB. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). Am J Cardiol. 2010 Oct 01; 106(7):999-1005.
Score: 0.081
-
Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahl?f B, Aurigemma GP, Rokkedal JE, Devereux RB. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens. 2010 Jul; 28(7):1541-6.
Score: 0.080
-
Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahl?f B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010 Jun; 19(3):169-75.
Score: 0.079
-
Chinali M, Aurigemma GP, de Simone G, Mishra RK, Gerdts E, Wachtell K, Boman K, Dahl?f B, Devereux RB. Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). Am J Cardiol. 2009 Oct 15; 104(8):1098-104.
Score: 0.076
-
McManus D, Aurigemma G. Clinical advances in diastolic heart failure. Minerva Cardioangiol. 2006 Dec; 54(6):695-713.
Score: 0.062
-
Vinch CS, Aurigemma GP, Simon HU, Hill JC, Tighe DA, Meyer TE. Analysis of left ventricular systolic function using midwall mechanics in patients >60 years of age with hypertensive heart disease and heart failure. Am J Cardiol. 2005 Nov 01; 96(9):1299-303.
Score: 0.057
-
Bashir Z, Chen EW, Tori K, Ghosalkar D, Aurigemma GP, Dickey JB, Haines P. Insight into different phenotypic presentations of heart failure with preserved ejection fraction. Prog Cardiovasc Dis. 2023 Jul-Aug; 79:80-88.
Score: 0.049
-
Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahl?f B, Aurigemma GP, Devereux RB. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002 Jul 09; 106(2):227-32.
Score: 0.046
-
Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, Meyer TE. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol. 2002 Feb 20; 39(4):664-71.
Score: 0.045
-
Zile MR, Green GR, Schuyler GT, Aurigemma GP, Miller DC, Cooper G. Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. J Am Coll Cardiol. 2001 Mar 15; 37(4):1080-4.
Score: 0.042
-
Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, Agabiti-Rosei E, Mancia G. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation. 2001 Feb 06; 103(5):678-83.
Score: 0.042
-
Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahl?f B, Smith G, Roman MJ, Ibsen H, Aurigemma GP, Devereux RB. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol. 2001 Jan 01; 87(1):54-60.
Score: 0.041
-
Chung ES, Perlini S, Aurigemma GP, Fenton RA, Dobson JG, Meyer TE. Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. J Hypertens. 1998 Dec; 16(12 Pt 1):1813-22.
Score: 0.036
-
Devereux RB, Pini R, Aurigemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise. J Hypertens. 1997 Aug; 15(8):801-9.
Score: 0.033
-
Gaasch WH, John RM, Aurigemma GP. Managing asymptomatic patients with chronic mitral regurgitation. Chest. 1995 Sep; 108(3):842-7.
Score: 0.029
-
Aurigemma GP, Silver KH, McLaughlin M, Mauser J, Gaasch WH. Impact of chamber geometry and gender on left ventricular systolic function in patients > 60 years of age with aortic stenosis. Am J Cardiol. 1994 Oct 15; 74(8):794-8.
Score: 0.027
-
Orsinelli DA, Aurigemma GP, Battista S, Krendel S, Gaasch WH. Left ventricular hypertrophy and mortality after aortic valve replacement for aortic stenosis. A high risk subgroup identified by preoperative relative wall thickness. J Am Coll Cardiol. 1993 Nov 15; 22(6):1679-83.
Score: 0.025
-
Bang CN, Gerdts E, Aurigemma GP, Boman K, Dahl?f B, Roman MJ, K?ber L, Wachtell K, Devereux RB. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2013 Oct; 31(10):2060-8.
Score: 0.025
-
Narayanan A, Aurigemma GP, Chinali M, Hill JC, Meyer TE, Tighe DA. Cardiac mechanics in mild hypertensive heart disease: a speckle-strain imaging study. Circ Cardiovasc Imaging. 2009 Sep; 2(5):382-90.
Score: 0.019
-
Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourci?re Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.
Score: 0.016
-
Wachtell K, Papademetriou V, Smith G, Gerdts E, Dahl?f B, Engblom E, Aurigemma GP, Bella JN, Ibsen H, Rokkedal J, Devereux RB. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Am Heart J. 2004 Sep; 148(3):538-44.
Score: 0.013
-
Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001 Aug 14; 104(7):779-82.
Score: 0.011
-
Sorgato A, Faggiano P, Aurigemma GP, Rusconi C, Gaasch WH. Ventricular arrhythmias in adult aortic stenosis: prevalence, mechanisms, and clinical relevance. Chest. 1998 Feb; 113(2):482-91.
Score: 0.008
-
Sharma M, Aurigemma GP, Meyer TE, Gaasch WH. Recurrent syncope after successful aortic valve replacement. Am Heart J. 1996 Jul; 132(1 Pt 1):194-7.
Score: 0.008